secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001104659-23-061486
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics elects three Class III directors, ratifies auditor at annual meeting
--------------------------------------------------------------------------------

- David M. Epstein, Wendy L. Dixon, and Kapil Dhingra elected as Class III directors to serve until 2026.
- Epstein received 26.4M votes for, 84k withheld; Dixon 19.1M for, 7.3M withheld; Dhingra 20.0M for, 6.4M withheld.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 with 31.0M for, 22k against, 18k abstain.
- Meeting held virtually May 16, 2023; 31.1M shares represented out of 36.5M outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465923061486/0001104659-23-061486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465923061486/tm2315952d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-061486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer